Serum Beta-2 Microglobulin as Biomarker in Chronic Lymphocytic Leukemia

ORIGINAL ARTICLE
Nora M. Mahgoub, Awad-Elkareem Abass, Nidal H. AL Sheikh, Esra B. AL Sheikh, Ezeldine K. Abdalhabib

 
For citation: Mahgoub NM, Abass AE, Al-Sheikh NH, Al-Sheikh EB, Abdalhabib EK. Serum Beta-2 Microglobulin as Biomarker in Chronic Lymphocytic Leukemia. International Journal of Biomedicine. 2024;14(4):591-594. doi:10.21103/Article14(4)_OA9
 
Originally published December 5, 2024
 

Abstract: 

Background: Beta-2 microglobulin (B2M) has been identified for many years as a reliable prognostic marker in patients with chronic lymphocytic leukemia (CLL). Our study aimed to determine the serum level of B2M in Sudanese CLL patients and correlate it with other clinical and hematological parameters.
Methods and Results: A cross-sectional study was conducted at the Radio Isotopes Centre of Khartoum in Sudan. Forty-six patients previously diagnosed with CLL were enrolled in the study, and 14 healthy individuals were also included to control the assessment of B2M. Out of the 46 CLL patients (30 men and 16 women), 32 patients underwent chemotherapy treatment, while 14 patients were untreated and newly diagnosed. Complete blood count was measured using Sysmex KX-21N-TOA. The serum B2M level was measured using solid-phase sandwich ELISA.
The absolute lymphocyte count was 31.3±26.8 (×109/L), with lymphocytosis in 93.8%. The mean platelet count was 158.5±66.4 (×109/L), and thrombocytopenia was noticed in 25% of the patients. The serum level of B2M was significantly higher in CLL than in healthy normal controls (7.9±6.1 mg/L versus 0.6±0.3 mg/L, P=0.000).
In CLL-untreated patients, the B2M level was also significantly higher than in treated patients: 18.1±5.2 mg/L versus 5.5±3.0 mg/L (P<0.0001). The B2M level was significantly higher in patients at stages III and IV than in stages I and II: 8.6.1±5.1 mg/L versus 2.7±0.3 mg/L (P<0.0001).
Conclusion: Serum B2M level correlates with the disease stages in CLL patients, and its determination could be useful in following up on CLL patients during the treatment or remission.

Keywords: 
beta-2 microglobulin • chronic lymphocytic leukemia • complete blood count
References: 
  1. Hus I, Podhorecka M, Bojarska-Junak A, Roliński J, Schmitt M, Sieklucka M, Wasik-Szczepanek E, Dmoszyńska A. The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol. 2006 Apr;17(4):683-90. doi: 10.1093/annonc/mdj120. Epub 2006 Mar 8. PMID: 16524977.
  2. Molica S, De Rossi G, Luciani M, Levato D. Prognostic features and therapeutical approaches in B-cell chronic lymphocytic leukemia: an update. Haematologica. 1995 Mar-Apr;80(2):176-93. PMID: 7628755.
  3. Chiorazzi N. Implications of new prognostic markers in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2012;2012:76-87. doi: 10.1182/asheducation-2012.1.76. PMID: 23233564.
  4. Drüeke TB, Massy ZA. Beta2-microglobulin. Semin Dial. 2009 Jul-Aug;22(4):378-80. doi: 10.1111/j.1525-139X.2009.00584.x. PMID: 19708985.
  5. Yewdell JW, Reits E, Neefjes J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat Rev Immunol. 2003 Dec;3(12):952-61. doi: 10.1038/nri1250. PMID: 14647477.
  6. Shi C, Zhu Y, Su Y, Chung LW, Cheng T. Beta2-microglobulin: emerging as a promising cancer therapeutic target. Drug Discov Today. 2009 Jan;14(1-2):25-30. doi: 10.1016/j.drudis.2008.11.001. Epub 2008 Dec 26. PMID: 19056512.
  7. Yang J, Yi Q. Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules. Cancer. 2010 Apr 1;116(7):1638-45. doi: 10.1002/cncr.24953. PMID: 20143445; PMCID: PMC2847067.
  8. Yoo C, Yoon DH, Kim S, Huh J, Park CS, Park CJ, Lee SW, Suh C. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma. Hematol Oncol. 2016 Mar;34(1):22-7. doi: 10.1002/hon.2188. Epub 2015 Feb 16. PMID: 25689467.
  9. Seo S, Hong JY, Yoon S, Yoo C, Park JH, Lee JB, Park CS, Huh J, Lee Y, Kim KW, Ryu JS, Kim SJ, Kim WS, Yoon DH, Suh C. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. Oncotarget. 2016 Nov 22;7(47):76934-76943. doi: 10.18632/oncotarget.12734. PMID: 27764777; PMCID: PMC5363560.
  10. Muta T, Iida S, Matsue K, Sunami K, Isoda J, Harada N, et al. Predictive significance of serum beta 2‑microglobulin levels and M‑protein velocity for symptomatic progression of smoldering multiple myeloma. Blood 2014; 124(21): 3379. 10.1182/blood.V124.21.3379.3379
  11. Wu L, Wang T, Gui W, Lin H, Xie K, Wang H, Gao T, Zhang X, Liu L, Han T, Tian Y, Hou L. Prognostic significance of serum beta-2 microglobulin in patients with non-Hodgkin lymphoma. Oncology. 2014;87(1):40-7. doi: 10.1159/000362670. Epub 2014 Jun 25. PMID: 24969158.
  12. Yoo C, Yoon DH, Suh C. Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor. Blood Res. 2014 Sep;49(3):148-53. doi: 10.5045/br.2014.49.3.148. Epub 2014 Sep 25. PMID: 25325033; PMCID: PMC4188779.
  13. Tsimberidou AM, Kantarjian HM, Wen S, O'Brien S, Cortes J, Wierda WG, Koller C, Pierce S, Brandt M, Freireich EJ, Keating MJ, Estey EH. The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients. Clin Cancer Res. 2008 Feb 1;14(3):721-30. doi: 10.1158/1078-0432.CCR-07-2063. PMID: 18245532.
  14. Gatto S, Ball G, Onida F, Kantarjian HM, Estey EH, Beran M. Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS). Blood. 2003 Sep 1;102(5):1622-5. doi: 10.1182/blood-2002-10-3264. Epub 2003 May 8. PMID: 12738677.
  15. Gentile M, Cutrona G, Neri A, Molica S, Ferrarini M, Morabito F. Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages. Haematologica. 2009 Jun;94(6):887-8. doi: 10.3324/haematol.2009.005561. PMID: 19483161; PMCID: PMC2688585.
  16. Alrayes MH, Abd Albaset HH. Significance of tumor necrosis factor- α and B2 microglobulin in patients having chronic lymphocytic leukemia. The Egyptian Journal of Hospital Medicine 2003; 12(1): 28-37. 10.21608/EJHM.2003.18242
  17. Di Giovanni S, Valentini G, Carducci P, Giallonardo P. Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia. Acta Haematol. 1989;81(4):181-5. doi: 10.1159/000205558. PMID: 2502891.
  18. Yee C, Biondi A, Wang XH, Iscove NN, de Sousa J, Aarden LA, Wong GG, Clark SC, Messner HA, Minden MD. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood. 1989 Aug 1;74(2):798-804. PMID: 2787680.
  19. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20;23(18):4070-8. doi: 10.1200/JCO.2005.12.516. Epub 2005 Mar 14. PMID: 15767647.
  20. Melillo L, Musto P, Tomasi P, Cascavilla N, Bodenizza C, Ladogana S, Carotenuto M. Serum beta 2-microglobulin in malignant lymphoproliferative disorders. Tumori. 1988 Apr 30;74(2):129-35. doi: 10.1177/030089168807400202. PMID: 3285553.
  21. Ibrahim S, Keating M, Do KA, O'Brien S, Huh YO, Jilani I, Lerner S, Kantarjian HM, Albitar M. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001 Jul 1;98(1):181-6. doi: 10.1182/blood.v98.1.181. PMID: 11418478.
  22. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood. 2004 Feb 15;103(4):1202-10. doi: 10.1182/blood-2003-07-2281. Epub 2003 Oct 23. PMID: 14576043.
  23. Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, Lerner S, Kurzrock R. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001 Jan 1;97(1):256-63. doi: 10.1182/blood.v97.1.256. PMID: 11133769.

Download Article
Received October 10, 2024.
Accepted November 19, 2024.
©2024 International Medical Research and Development Corporation.